Article

Stem cells may protect retina from progressive degeneration, study says

A proprietary purified human neural stem cell product (HuCNS-SC, StemCells), when transplanted into a well-established animal model, may protect the retina from progressive degeneration, according to researchers.

Portland, OR-A proprietary purified human neural stem cell product (HuCNS-SC, StemCells), when transplanted into a well-established animal model, may protect the retina from progressive degeneration, according to researchers.

In this preclinical study, conducted by Raymond Lund, PhD, researcher and professor, Casey Eye Institute, Oregon Health and Science University, Portland, and his research team, stem cells were transplanted into the Royal College of Surgeons rat, a well-established animal model of retinal degeneration.

The study showed that the stem cells survived the transplants and engrafted, and the eyes transplanted with the cells showed preservation of the photoreceptors and stabilization of visual function.

"This study confirms the results of previously published academic studies evaluating neural stem cell transplantation into the retina and provides us with the rationale to pursue clinical testing of HuCNS-SC cells for retinal disorders,” said Stephen Huhn, vice president and head of the CNS program at StemCells.

"We are already conducting additional preclinical studies and a pre-investigational new drug (IND) meeting has been scheduled with the FDA in December 2008 to determine the pathway to a successful IND filing," he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.